Background
==========

Antibody-based anti-cancer pharmacodelivery strategies critically rely on the availability of good-quality tumour markers, allowing a clear differentiation between diseased tissue and healthy organs. Markers of the tumour neovasculature are particularly attractive, because of the dependence of tumours on new blood vessels to sustain growth and invasion, and because of the accessibility of these structures from the bloodstream. Furthermore, angiogenesis is a common feature of virtually all malignancies \[[@B1],[@B2]\].

The alternatively spliced extra domain A (EDA) and B (EDB) of fibronectin and A1 domain of tenascin-C represent three of the best-characterized markers of angiogenesis and have been reported to be expressed around the neo-vasculature and in the stroma of virtually all types of aggressive solid tumours. Three human monoclonal antibodies specific to these targets have been developed by our groups and moved to clinical trials: L19 (specific to EDB) \[[@B3]\], F8 (specific to EDA) \[[@B4]\] and F16 (specific to the A1 domain of tenascin-C) \[[@B5]\]. Several antibody derivatives, based on the modification of L19, F8 or F16 with cytokines or iodine radionuclides, are currently investigated in Phase I and Phase II clinical trials in patients with cancer and with rheumatoid arthritis \[[@B6],[@B7]\]. These biopharmaceuticals are called L19-^124^I, L19-^131^I, L19-IL2, L19-TNF, F8-IL10, F16-^124^I, F16-^131^I, F16-IL2, indicating the modular nature of these derivatives, in which the antibody moiety is used to deliver a payload at the site of disease.

The staining patterns of the L19 and F16 antibody in head and neck tumours \[[@B5],[@B8]\] have previously been published by our group in separate articles, but the relative staining intensities of the two antibodies have so far not been compared. Furthermore, a radioiodinated version of the L19 antibody has been tested in scFv format in a small immunoscintigraphic clinical study in patients with head and neck squamous cell carcinomas (SCC), observing tumour localization in 4 of 5 patients \[[@B9]\]. More recently, radioiodinated derivatives of both L19 and F16 antibodies in SIP format \[[@B5],[@B10]\] have been studied in Phase II clinical trials in over 100 patients with cancer, including head and neck cancer patients \[[@B6]\]\[unpublished results\].

In this article, we report the first comparative analysis of expression patterns for the extra domains EDB and EDA of fibronectin and A1 of tenascin-C in both primary and metastatic head and neck cancer lesions.

Methods
=======

Specimens
---------

A total of 40 freshly frozen OCT embedded tissue samples were obtained from the University Hospital of Salzburg (Austria), Department of ear-nose-throat diseases. This study was examined by the ethical committee of the province Salzburg and patient consents for the tissue collection were obtained prior to surgery. The specimens were collected during major head and neck tumour operations (table [1](#T1){ref-type="table"}). The tissues were stored at -80°C. Sections of 10 μm were cut.

###### 

Description of samples used for the immunofluorescence analysis

  -----------------------------------------------------------------------------------------------------------
  **Sample No**.   Primary tumor/\        Tissue origin                              Histological result^2^
                   LN metastasis^1^                                                  
  ---------------- ---------------------- ------------------------------------------ ------------------------
  1                tumour                 parotid gland                              PA

  2                metastasis             lymph node                                 SCC

  3                tumour                 hypopharynx                                SCC

  4                tumour                 hypopharynx                                SCC

  5                tumour                 uvula                                      SCC

  6                tumour                 skin (left auricle)                        BCC

  7                metastasis             lymph node                                 SCC

  8                tumour                 hypopharynx                                SCC

  9                metastasis (from 8)    lymph node                                 SCC

  10               metastasis             lymph node                                 SCC

  11               tumour                 skin (nose)                                SCC

  12               tumour                 hypopharynx                                SCC

  13               tumour                 oral cavity (tongue)                       SCC

  14               metastasis (from 13)   lymph node                                 SCC

  15               metastasis (from 8)    lymph node                                 SCC

  16               tumour                 parotid gland                              PA

  17               tumour                 oropharynx                                 SCC

  18               tumour                 oropharynx                                 SCC

  19               tumour                 parotid gland                              PA

  20               tumour                 parotid gland                              PA

  21               tumour                 hypopharynx                                SCC

  22               tumour                 larynx (vocal cord)                        SCC

  23               tumour                 larynx                                     SCC

  24               tumour                 larynx                                     SCC

  25               metastasis             lymph node                                 CS

  26               tumour                 oropharynx (tonsil)                        SCC

  27               tumour                 larynx                                     SCC

  28               tumour                 oropharynx                                 SCC

  29               tumour                 supraglottis                               SCC

  30               tumour                 supraglottis                               SCC

  31               tumour                 supraglottis                               SCC^3^

  32               tumour                 oral cavity (lower jaw - alveolar crest)   SCC

  33               tumour                 larynx (glottis - posterior commissure)    SCC

  34               tumour                 oral cavity (palatal arch)                 SCC

  35               tumour                 nasopharynx                                SCC

  36               metastasis             lymph node                                 PDTC

  37               metastasis             lymph node                                 SCC

  38               tumour                 oropharynx (vallecula epiglottica)         SCC

  39               tumour                 larynx (epiglottis)                        SCC

  40               tumour                 larynx (epiglottis)                        SCC
  -----------------------------------------------------------------------------------------------------------

^1^Indication of primary tumour sample (LN: cervical lymph node). ^2^Abbreviations: SCC: squamous cell carcinoma; PA: pleomorphic adenoma (benign); CS: carcinosarcoma; PDTC: poorly differentiated thyroid carcinoma; BCC: basal cell carcinoma. ^3^Status post radiotherapy.

Immunofluorescence staining
---------------------------

The L19 antibody, specific to the extra domain B (EDB) of fibronectin, the F8 antibody, specific to the extra domain A (EDA) of fibronectin, and the F16 antibody, specific to the extra domain A1 of tenascin-C, have been described before \[[@B3]-[@B5]\]. All antibodies were isolated from ETH2 antibody libraries, affinity matured, had dissociation constants in the low nanomolar range and exhibited kinetic dissociation constants *k*~off~towards the respective antigens \<10^-2^s^-1^in real-time interaction analysis experiments on a BIAcore 3000 instrument (GE Healthcare, Zurich, Switzerland). As a negative control the antibody KSF was used. KSF is specific to hen egg lysozyme and does not show any specificity towards human antigens. All antibodies were biotinylated and carried a comparable number of biotin molecules.

For immunofluorescence, a double staining for EDA, EDB resp. TnC-A1 and von Willebrand factor was performed. The following primary antibodies were used: biotinylated F8, L19, F16 and KSF (negative control antibody) in small immunoprotein format (SIP) (2 μg/ml for all four antibodies) and polyclonal rabbit anti-human von Willebrand factor (Dako, Glostrup, Denmark). For detection of the biotinylated SIPs Streptavidin Alexa Fluor 488 (Invitrogen, Basel, Switzerland) was used. As secondary detection antibody for the anti-von Willebrand factor antibody Alexa Fluor 488 goat anti-rabbit (Invitrogen, Basel, Switzerland) antibody was used.

Cryosections were fixed in chilled aceton, rehydrated in PBS (100 mM NaCl, 30 mM Na~2~HPO~4~, 20 mM NaH~2~PO~4~, pH 7.4) and blocked with 20% goat serum in PBS. Primary antibodies were added in a final concentration of 2 μg/ml in 3% bovine serum albumin (BSA)/PBS solution and incubated for 1 h. After washing in PBS secondary antibodies were added in 3% bovine serum albumin (BSA)/PBS solution and incubated for 1 h. Sections were washed in PBS and mounted with fluorescent mounting medium (Dako, Glostrup, Denmark) and analyzed with a confocal laser scanning microscope (LSM 510 META, Zeiss, Oberkochen, Germany). Microscopic exposure times were identical for all antibodies. Images were further processed using the ImageJ software <http://rsb.info.nih.gov/ij>.

Semi-quantitative evaluation of results
---------------------------------------

Staining intensities of the extra domains A and B of fibronectin and the A1 domain of tenascin C were independently assessed by experienced investigators. Staining was scored using 7 scores: 0, 0.5, 1, 1.5, 2, 2.5 and 3, according to a training table, representing a selection of the corresponding staining intensities as reference. Data are expressed as the mean ± standard error of the mean.

Results and Discussion
======================

The staining intensities of biotinylated derivatives of the L19, F8 and F16 antibodies in 40 frozen specimens of head and neck cancer were studied by three-colour immunofluorescence microscopy. The tissue series included tumours of the oral cavity, the pharynx and the larynx \[table [1](#T1){ref-type="table"}\]. Primary benign lesions, malignant tumours as well as metastatic cancer specimens were analyzed. The three antibodies L19, F8 and F16 had comparable high affinities towards their cognate antigen and were used in identical concentrations. The KSF antibody, specific to hen egg lysozyme and with no known reactivity towards human antigens \[[@B11]\], was used as negative control (data not shown). Figure [1](#F1){ref-type="fig"} shows representative immunofluorescence findings with the three antibodies (green) in different tumour sections. Cell nuclei were stained with DAPI (blue), while blood vessels were coloured in red using an anti-von Willebrand antibody. In most specimens, all three antibodies exhibited a diffuse stromal staining, similar to previously described patterns of fibronectin and tenascin-C expression \[[@B12],[@B13]\]. Interestingly, some specimens exhibited striking differences in staining by the three antibodies \[Figure [1](#F1){ref-type="fig"}\]. This observation suggests that, while at least one of the three antibodies is generally capable of intensely staining a given tumour, an individualized treatment procedure (e.g., choice of L19, F8 or F16 based on immuno-PET or immunofluorescence procedure) may represent the most logical avenue for offering the best possible antibody to any given patient.

![**Immunofluorescence staining of head and neck cancer samples**. The expression patterns and intensities of the splice isoforms extra domain A (EDA) and extradomain B (EDB) of fibronectin and the A1 domain of tenascin C were detected with the antibodies F8, L19 and F16, respectively (shown in green). A co-staining with an anti-von Willebrand factor antibody that stains blood vessels (red) and Dapi (blue) was performed. Abbreviations: SCC: squamous cell carcinoma; PA: pleomorphic adenoma.](1758-3284-3-25-1){#F1}

Figure [2](#F2){ref-type="fig"} presents a semi-quantitative analysis of staining intensities of L19, F8 and F16, ranging from 0 (absent), to 3 (+++). Independent investigators assessed all pictures, assigning a scoring intensity to each specimen. The average of these values and the corresponding standard error were displayed in the figure. Primary tumours and metastatic tumour lesions as well as primary benign and malign tumours were analyzed, as well as tumour samples from different anatomical locations (oral cavity, larynx and pharynx). On average, F8 and F16 exhibited similar staining intensities, which were typically stronger than L19. As a consequence, armed antibodies based on F8 or F16 may represent the best choice for the treatment of head and neck cancer, whereas L19 may be more appropriate for other cancer types which strongly express the EDB domain of fibronectin (e.g., kidney cancer; \[[@B7]\]). However, it cannot be excluded that the weaker staining observed for EDB may be a consequence of lower stability of this antigen, which has been reported in case of tissue section storage at -80°C for longer than 20 days \[[@B14]\]. In a previous study, a radioiodinated version of the L19 antibody has been tested in scFv format in a small immunoscintigraphic clinical study in patients with head and neck squamous cell carcinomas. Successful targeting of the primary tumour could be achieved in 4 out of 5 patients \[[@B9]\]. Further imaging studies are needed to reveal whether targeting of F16 and F8 is superior to L19 in head and neck cancer patients. Indeed, two Phase II clinical trials with SIP(L19) \[[@B6]\] and SIP(F16) labelled with ^124^I \[[@B15]\] are currently being performed.

![**Analysis of staining intensities**. Comparison of staining intensities obtained with the antibodies F8, L19 and F16 in A) primary tumours and metastasis tumour samples and in B) primary benign and primary maligant tumour specimens. C) Average staining intensities of tumours of the oral cavity, the pharynx or the larynx. Standard Errors of the Mean of scoring values are displayed.](1758-3284-3-25-2){#F2}

Conclusions
===========

The majority of head and neck cancer types exhibited a diffuse pattern of expression for splice isoforms of fibronectin and of tenascin-C. The clinical stage antibodies F8 and F16 stained tumours more intensely compared to L19 and may thus represent the most suitable candidates to be used as vehicles for pharmacodelivery applications.

Competing interests
===================

DN is the founder and shareholder of Philogen S.p.A. (Siena, Italy), the company that owns the F8, L19 and F16 antibodies.

Authors\' contributions
=======================

KS performed the immunofluroescence stainings, evaluated the results and assisted in preparing the manuscript. DN proposed, designed, and supervised the project, and wrote and revised the manuscript. CR performed the microscopical analysis, evaluated the results and revised the manuscript. GM designed the project, performed the surgery together with MRK, and wrote and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements
================

Financial support from the ETH Zurich, the Swiss National Science Foundation (grant \# 310030_126988) and European Union Projects IMMUNO-PDT (grant \# LSHC-CT-2006-037489) and ADAMANT (HEALTH-FP7-2008-201342) is gratefully acknowledged.
